Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.

ABSTRACT:

Purpose

Endocrine therapies include aromatase inhibitors and the selective estrogen receptor (ER) downregulator fulvestrant. This study aimed to determine whether the reported efficacy of fulvestrant over anastrozole, and high- over low-dose fulvestrant, reflect distinct transcriptional responses.

Experimental design

Global gene expression profiles from ERα-positive breast carcinomas before and during presurgical treatment with fulvestrant (n = 22) or anastrozole (n = 81), and corresponding in vitro models, were compared. Transcripts responding differently to fulvestrant and estrogen deprivation were identified and integrated using Gene Ontology, pathway and network analyses to evaluate their potential significance.

Results

The overall transcriptional response to fulv

SUBMITTER: Patani N 

PROVIDER: S-EPMC4119788 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature